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Objective: To provide an overview of the literature describing the role of asporin, a small leucine-rich
proteoglycan (SLRP), in osteoarthritis (OA).
Method: A literature search was performed and reviewed using the narrative approach.
Results: As a class I SLRP member, asporin, is distinct from other SLRPs. Accumulating evidence dem-
onstrates the involvement of asporin in OA pathogenesis. Many human studies have been conducted to
explore the association between the D-repeat polymorphisms and OA susceptibility, but these yield
inconsistent results. Possible mechanisms for the involvement of asporin in OA pathology include its
inﬂuence on TGF-b (transforming growth factor-b) signaling pathways and collagen mineralization. To
date, no studies were found to use an asporin-deﬁcient animal model that would help to understand
disease mechanisms. Many issues must be addressed to clarify the link between asporin and OA to
provide a novel therapeutic strategy for OA, perhaps through controlling and modifying the TGF-b-ECM
system.
Conclusions: Studies examined demonstrate the involvement of asporin in OA pathogenesis, and possible
mechanisms by which asporin may be involved in this process have been proposed. However, large-scale
interracial studies should be conducted to investigate the association between asporin and OA, and
further investigations are needed to obtain a better understanding of the disease mechanism, develop
novel therapeutic strategies, and explore new approaches for diagnosis of OA.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
As the most prevalent form of arthritis in humans, osteoarthritis
(OA) is the leading skeletal disease that causes disability after
middle age. In the United States, over 25 million people suffered
from clinical OA in 20051. It is estimated that 15.4% and 42.8% of
Chinese females aged 60 years or older could be diagnosed as
symptomatic and radiographic knee OA, respectively2. Unfortu-
nately, however, current therapeutic approaches only slow pro-
gression of OA rather than prevent it. Although its etiology remains
unknown, it is believed that OA is a polygenic disease controlled by
genetic and environmental factors1,3. Some genetic linkage and
candidate genes have been reported to be associated with sus-
ceptibility to OA, suggesting that genetic factors play an important
role in its development4. The roles of small leucine-rich pro-
teoglycans (SLRPs), a group of biologically active components of theo: G.-X. Ni, Department of
outhern Medical University,
86-20-62787924.
ternational. Published by Elsevier Lextracellular matrix (ECM) of many tissues, in OA pathogenesis
have recently been reviewed by our group5.
Like many other SLRPs, asporin, a class I SLRP, exerts an
important inﬂuence on cell metabolism, including cell differentia-
tion, proliferation, migration, and apoptosis6,7. Previous studies
revealed the involvement of asporin in the pathogenic mechanisms
of disc degenerative disease8 and periodontal disease9,10. The
following review will summarize the recent literature concerning
the role of asporin in OA pathogenesis, and the potential mecha-
nism by which it might be involved in this process.Structure and tissue distribution of asporin
The growing SLRP family comprises 18 members, which are
grouped into ﬁve distinct classes, based on the structural prop-
erties of their core proteins5. Asporin was ﬁrst discovered and
named in 2001 by Lorenzo et al.11 and Henry et al.12. It was
simultaneously and independently discovered by Yamada et al.10,
and identiﬁed as “periodontal ligament-associated protein 1(PLAP-
1)” because it was speciﬁcally expressed in the periodontal liga-
ment (PDL).td. All rights reserved.
Table I
Characteristics of asporin, decroin and biglycan
Asporin Decorin Biglycan
Gene location 9q22-9q21.3 12p76 Xq28-ter76
Proteoglycan? No12 Yes64 Yes77
Abundant in
joint tissue
Periosteum, PDL,
liver, heart, aorta,
uterus, predentin
Tendon, cartilage,
muscle, skin,
kidney, muscle,
predentin
Skin, tendon,
bone, cartilage,
PDL, kidney,
muscle,
predentin
Protein core 42 36 38
Upregulated
in diseases
OA, Scleroderma,
DDD
Osteogenesis
imperfecta,
Ehlers-Danlos
syndrome, OA8,11
Fibrosis and
atherosclerosis
TGF-b Binding
sites
P33-373(mainly),33-167,
P48-167,P279-37353
P155-260(mainly),
P45-359, P63-19078
P208-21679
Collagen
binding
sites
The 10e12th LLR63 The 4e5th80,
6th LLR81,
Factors
related to
expression
TGF-b,BMP TGF-b,EGFR,RTK,
MET,IGF-IR21
TGF-a/TGF-b,
IL, TNF-a,BMP79
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on human chromosome 9q22-9q21.3, which contains the ECM
protein 2 gene, osteoadherin (class II SLRP) and osteoglycin/mim-
ecan (class III SLRP) genes12,13. Similar to two other class I SLRP
members (decorin and biglycan), asporin contains an internal
stretch of 10 tandem leucine-rich repeats (LRR) (Fig. 1), each of
which contains 20e30 amino acids and is inserted by leucine res-
idues in ﬁxed conserved regions. Asporin consists of 380 amino
acids, and it contains a putative propeptide, four cysteines on the N-
terminus and two cysteines on the C-terminus11. Notably, the N-
terminal regions of decorin and biglycan are substituted with one
and two chondroitin/dermatan sulfate chains14,15, respectively.
Although its amino-acid sequence is 50%/70% identical to that of
decorin/biglycan12,14, asporin differs from these two class I SLRPs
(Table I). Asporin has distinguishing characteristics: (1) it possesses
a unique stretch of aspartic acid residues (D-repeat) in its N-ter-
minal region. The number of D-repeats varies from 9 (D9) to 20
(D20), and each variant with a different number of D-repeats may
play a different role in OA pathogenesis (discussed below)9,11,14. (2)
It does not ﬁt the strict deﬁnition of a proteoglycan because there is
no consensus sequence for glycosaminoglycan attachment be-
tween the propeptide and the amino-terminal cysteine motif11,12,16
(Fig. 1 and Table I).
Asporin protein has been found to be expressed in many tissues.
In mouse embryos, it is expressed in perichondrium or periosteum
of maxilla, vertebrae, mandible, and long bones, but not in epiph-
yseal cartilage12,14. In humans, it is expressed in aorta, uterus, heart,
liver, and abundantly in articular cartilage9,11,12,17, PDL, and dental
follicle18,19. A recent proteomic study reported that asporin content
in meniscus is much higher than in the medial tibial condyle and
the femoral head cartilage20. Like decorin and ﬁbromodulin21,
asporin directly binds TGF-b, and, subsequently, binds to collagen
by way of its LRR domain. Its N-terminal extension remains avail-
able to interact with other matrix constituents, including ﬁbers of
collagen, thus playing a role in collagen ﬁbrillogenesis and
metabolism11,17.Involvement of asporin in OA pathogenesis
Evidence suggests the involvement of asporin in OA patho-
genesis. Asporin expression is increased in OA cartilage asFig. 1. Schematic diagram of class I SLRP molecular structure. The structure of asporin is sim
and C-termini, and signal peptides in the N-terminus. However, asporin is not a proteoglycan
present different characteristics that depend upon the number of aspartatic acid residues. S
line: N-linked glycosylation site; arrow: O-linked glycosylation site.compared with normal cartilage16. Further, in vitro evidence
shows that asporin acts as a negative regulator of chondrogenesis
by inhibiting TGF-b function20. More direct evidence comes from
human studies, which investigated the association between D-
repeat polymorphisms and OA susceptibility (Table II). However,
the ﬁndings reported were contradictory. In Japanese and Chi-
nese Han populations, D14 was found to be a risk factor in
development of knee OA while, D13 was found to be a protective
factor against OA in some Japanese22,23. However, similar asso-
ciations with knee/hip OA were not demonstrated among Cau-
casians in the United States24 and Spain25, and a weak association
was detected in Caucasian men who had undergone knee
replacement surgery in the United Kingdom26. Moreover, asporin
was found to be associated with hand OA in the Netherlands27.
An association with D-repeat polymorphisms was also conﬁrmed
for knee OA in a Greek population28,29. Further, other alleles
(D12, D15, or D16) were associated with OA either as a risk factor
or a protective factor in Mexican30 and Iranian31 study pop-
ulations. Despite positive associations found in some study
populations, when data are stratiﬁed by ethnicity, the results ofilar to that of decorin and biglycan in that they all have LRR, cysteine regions on both N-
because of the absence of a glycosaminoglycan attachment site. Moreover, asporin may
: signal peptide; D: aspartic acid (D)-repeats; C: cysteine region; Blue box: LRR; dashed
Table II
Studies that examined associations between asporin and OA
Country Year OA site Samples Findings Ref.
Cases Controls
Japan 2005 Knee, hip 986 374 The frequency of D14 allele increased with OA severity while D13 presented a protective effect 22
United Kingdom 2005 Knee, hip 1182 748 No signiﬁcant association was found between OA and asporin except for the man who had
undergone hip replacement
26
Greece 2005 Knee 155 190 D15 allele could be a risk factor for OA 28
Spain 2005 Knee, hip 188 155 No signiﬁcant association between OA and asporin was found 25
China 2006 Knee 218 454 D14 allele could lead to OA 23
Korea 2007 Knee 190 367 Knee OA was only associated with asporin in women 82
Greece 2007 Knee 158 193 D14/D15 can be a risk factor with the presence of CALM1 29
United States 2008 Hand, knee 786 513 No signiﬁcant association was found between OA and asporin 24
Netherlands 2012 Hand 251 725 Asporin was associated with hand OA progression 27
Mexico 2013 Knee 218 222 D16 allele trended to be a risk factor; D12 allele could be a protective factor 30
Iran 2013 Knee 100 100 D15 allele could be a risk factor for women only 31
L. Xu et al. / Osteoarthritis and Cartilage 23 (2015) 933e939 935meta-analyses fail to demonstrate a relationship between
asporin and OA32e34.
The reasons for contradictory ﬁndings are unknown. Allele fre-
quencies may be an important factor. For instance, the proportions
of D13/D14/D15 among a control population in the United Kingdom
(50.3%/12.4%/22.1%)26 were similar to those of a control population
in Spain (42.2%/12.6%/25.5%)25, but different from those of a control
population in Japan (64%/4.8%/4.5%)22. However, the inhibitory
ability does not correlate with the length (number of amino acids)
of a single D-repeat22,32, because the D14 allele has a dominant
inhibitory effect while D15 and D16 alleles do not. From the
perspective of molecular structure, the D-repeats in asporin are
adjacent to a Zn2þ-binding domain, which is critical to conforma-
tional regulation in decorin35,36, which binds to ﬁbronectin and
collagen (types I, IV, and V) in a Zn2þ-dependent manner31. Hence,
it is speculated that D-repeat polymorphisms in asporin may alter
the conformation of collagen resulting in differences in its func-
tions. D-repeats might inﬂuence asporin function, just as the D-
repeat in osteopontin acts as a Ca2þ-binding domain and affects its
function37. Other factors may contribute to allele-speciﬁc effects on
OA development, including ethnic diversity, different environ-
mental and genetic backgrounds, sample inclusion criteria, and
techniques that are insufﬁcient to detect minor associations.
Therefore, more work is required to determine the signiﬁcance of
asporin polymorphisms in a large-scale population study to deﬁne
the effects of D-repeats on OA susceptibility.
Possible mechanisms for the involvement of asporin in OA
pathogenesis
Although accumulating evidence demonstrates the involvement
of asporin in OA pathogenesis, its precise mechanism is still not
understood. The involvement of asporin in the development of OA
may be associated with the following potential mechanisms.
TGF-b signaling pathway
Many SLRPs inﬂuence cellular functions through binding and
modulating members of the TGF-b superfamily5,38. For example,
decorin was reported to inhibit the TGF-b signaling pathway in
both human39 and rat models40,41. Biglycan and ﬁbromodulin
decreased the sequestration of TGF-b and led to overactive TGF-b
signal transduction42. Similarly, a key role for asporin is to bind to
TGF-b, and thereby inﬂuence various cellular functions. In a human
study, Sakao et al. reported that the ratio of asporin mRNA to TGF-b
mRNA in cartilage and subchondral bonewas higher in an OA group
compared with a non-OA group, and was positively correlated with
the severity of OA43. Furthermore, Nakajima et al. reported that thesmall interfering RNA (siRNA) mediated knockdown of asporin
promoted the expression of cartilage marker genes and TGF-b1,
implying a potential inhibitory effect for asporin16.
Currently, the TGF-b superfamily, comprising more than 30
members, can be categorized into subclasses: bone morphogenetic
proteins (BMPs), activins, and TGF-bs44. TGF-b has three isoforms:
TGF-b 1, TGF-b 2, and TGF-b 3, which demonstrate a high degree of
homology of 84e92%44,45. TGF-b is initially secreted as an inactive
propeptide (latency associated peptide, LAP) with latent TGF-b
binding proteins, but can be activated by cleavage and dissociation
of LAP44,45. The activated TGF-b (aTGF-b) interacts with and signals
through TGF-b type I and type II serine/threonine kinase receptors
(TGF-b RI and RII), and their intracellular effectors, Smads45. TGF-b
RI has seven subtypes known as activin receptor-like kinases 1e7
(ALK1e7)46. When ALK is recruited by phosphorylating the serine/
threonine residues, TGF-b binds to active TGF-b RII to form a
complex, which can induce the phosphorylation of the receptor-
Smads (R-Smads, including Smad1/2/3/5/8)39. The phosphory-
lated R-Smad then combines with common-Smad (Smad4) to play
a regulatory role in sequential intracellular reactions47,48 [Fig. 2(A)]
by stimulating chondrocyte terminal differentiation to begin bone
formation by physically interacting with runt-related transcription
factor 2 (Runx2)49. Notably, ALK1 signaling involves phosphory-
lating the Smad1/5/8 pathway while ALK5 signaling involves
phosphorylating the Smad2/3 pathway45. Signalings through ALK1
(Smad1/5/8) or ALK5 (Smad2/3) can induce opposite effects on
chondrocytes. Smad1/5/8 stimulates, but Smad 2/3 inhibits, matrix
metalloproteinase (MMP)-13 expression, synovial ﬁbrosis, cartilage
erosion, osteophyte formation at the joint margins, and sclerosis of
the subchondral bone50 (Fig. 2). Together, ALK1 and ALK5 may act
as a receptor switch to control chondrocyte homeostasis.
Through binding to TGF-b, asporin can inﬂuence cellular func-
tions. Nakajima et al. noticed that in ATDC5 cells (an in vitromouse
model for chondrogenesis)51,52 recombinant asporin inhibited TGF-
b binding to TGF-b RI and RII, and TGF-b-induced phosphorylation
of Smad in a dose-dependent manner [Fig. 2(A)]16. Recombinant
asporin and TGF-b through several peptide sites: peptide 159-205
(P159-205), P33-373, P33-167, P48-167 and P279-37316,53,54
(Table I). Although each site differs in its binding ability, all of
them can impede the dimerization of TGF-b RII to affect the sta-
bility of the TGF-b RI and RII complexes, thus hindering TGF-b-
induced chondrogenesis43,53,54. Because each site has the same
number of LRR, the inter-site difference in binding ability may be
due to the different positions of peptides and/or the non-identical
structure of LRR53. Alternatively, TGF-b may regulate asporin
expression in chondrocytes by way of the canonical TGF-b/Smad
pathway16. Administration of Smad3 (but not Smad2) siRNA
effectively depresses TGF-1-induced asporin expression, however,
Fig. 2. A model depicting the involvement of asporin in the mechanism of OA pathogenesis. (A) Under normal circumstances, TGF-b receptor I in the cytoplasm is phosphorylated
and activated by TGF-b receptor II (the blue dotted arrow). Activated TGF-b receptor I phosphorylates R-Smad (Smad1/2/3/5/8) and induces it to combine with Co-Smad (Smad4) to
form a complex, which plays a regulatory role in gene expression (e.g., Runx2). ALK1 and ALK5 have opposing effects on Runx2 and may act as a “receptor switch”. The over-
expressed asporin (the red pentagon) can bind to either TGF-b or TGF-b RI and RII, thus inﬂuencing normal TGF-b expression and function. (B) A model depicting how asporin
leads to OA. Abnormal loading and other stimuli (aging, obesity, injury, and ailments) can cause cartilage breakdown. Normally, impaired tissues can self-repair and respond to
mechanical demands by chondrogenesis and osteogenesis. Asporin could interfere with these processes and inhibit the formation of collagen and aggrecan through the TGF-b/Smad
pathway. Further, asporin could bind directly to collagen and induce its mineralization. Once the normal expression of TGF-b is inhibited, downstream cytokines (e.g., ILs, MMP, etc.)
could increase in the articular cartilage, thus preventing the accumulation of collagen and aggrecan, stopping repair of cartilage, and accelerating the development of OA.
L. Xu et al. / Osteoarthritis and Cartilage 23 (2015) 933e939936overexpression of Smad3 promotes asporin expression at both the
protein and mRNA levels54. Thus, asporin and TGF-b may create a
regulatory feedback loop [Fig. 2(A)].
TGF-b1-induced asporin expression is selectively mediated by
Smad3, which leads to a question: can asporin reversibly and
selectively inhibit one or several of the R-Smad pathways (Smad1/
2/3/5/8)? Previously, a particular regulatory effect of decorin on the
Smad2 pathway was found in EhlerseDanlos syndrome, a disease
that involves unbalanced expression of MMPs, tissue inhibitor of
metalloproteinases (TIMPs), proteoglycans, and collagens55,56.
Existing evidence57 shows that ALK1/ALK5 is increased in aging
mouse cartilage and experimental OA, but it is not clear whether
asporin is involved or not. Few studies have investigated the po-
tential inhibitory mechanism of asporin on a speciﬁc Smad
pathway. Nevertheless, we hypothesized that asporin inhibited the
Smad2/3 pathway because anabolic pathway tends to be sup-
pressed by asporin. Further investigation is warranted to clarify the
mechanism by which asporin inhibits TGF-b and induces OA, and
the association between D-repeats polymorphism and OA
susceptibility.
TGF-b is a regulator of osteogenesis and chondrogenesis in
articular cartilage and subchondral bone. Through its binding to
TGF-b, asporin can inhibit its downstream expression and induce
OA. Macroscopically, the inhibitory effect of asporin on TGF-b leads
to suppression of chondrogenesis in vitro and decreases the accu-
mulation of collagen and proteoglycan22,44, because TGF-b can play
a role in repair of cartilage early in the development of OA and it can
inhibit collagenase48,58. At the molecular level, TGF-b counteracts
IL-1 (interleukin-1), which is thought to suppress proteoglycan
synthesis59, stimulates nitric oxide production60, and increases
MMPs by upregulating a Disintegrin and Metalloproteinase with
Thrombospondin Motifs (ADAMTS) and TIMPs44,50. Moreover, TGF-
b was reported to induce Runx243, which can lead to hypertrophic
differentiation of articular chondrocytes and stimulate ADAMTSand MMP-13. ADAMTS and MMP-13 can degrade aggrecan, and
MMP-13 is efﬁcient in degrading type II collagen61,62. Because of the
degradation and breakdown of collagen and aggrecan, a potential
OA trigger could be established in the cartilage and subchondral
bone, and other stimuli such as an injury or ailment could accel-
erate the development of OA [Fig. 2(B)].
In addition, asporin/PLAP-1 in mouse cells cloned from PDL
tissues suppressed both natural and BMP-2-inducedmineralization
of the PDL cells. Further, BMP-2-induced differentiation of PDL cells
was found to be increased when asporin/PLAP-1 was eliminated by
RNA interference18. These results suggest that asporin might play a
regulatory role by BMP-2.
Changes in collagen mineralization
In addition to its inﬂuence on the canonical TGF-b pathway,
asporin bind directly to collagen and calcium to induce the bio-
mineralization of collagen63. The role of asporin in biomineraliza-
tion is similar to its expression pattern in osteoblast progenitor
cells, which regulates intramembranous bone formation and
cartilage recovery54,63. Sebastian et al. found that even at a low
concentrations, asporin could accelerate the formation of bone-like
nodules and increase their size in MG63 cells (cells that exhibit an
osteoblast phenotype and can be stained with Alizarin Red when in
the presence of calcium)64e66, which indicated that asporin inﬂu-
enced the calciﬁcation of collagen in vitro. However, this effect was
not duplicated by other SLRP members. Although some of them can
bind to collagen67, asporin is probably the only SLRP that induces
collagen mineralization, and regulates the initial deposition of hy-
droxyapatite, and it may be implicated in the progression of pa-
thology such as OA63.
Asporin can regulate collagen calciﬁcation by triggering bio-
mineralization, and the primary collagen binding sites locates in
10e12th LRR close to the C-terminal of the protein63,64.
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osteopontin63,68 and bone sialoprotein63,69 which can bind to cal-
cium to inﬂuence hydroxyapatite crystal formation in collagen and
thus change the bone crystal size70. Many other SLRPs, including
decorin71, biglycan71, ﬁbromodulin72, and lumican73 were
conﬁrmed to bind to collagen, but cannot mineralize collagen.
There are competitive effects among SLRP members. For instance,
biglycan can compete with decorin for binding collagen, while
decorin can inhibit asporin from binding to collagen and inducing
collagen mineralization. Similar competition can also be found
between lumican and ﬁbromodulin because they share the same
binding site (LRR7)72e74. The collagen-binding competition be-
tween decorin and asporin may maintain collagen metabolic bal-
ance, and regulate ﬁbril and collagen shape and diameter. Although
decorin inhibited asporin-collagen binding and asporin-induced
mineralization of collagen, decorin was found to have a
calciﬁcation-increasing effect when it was combined with bone
sialoprotein. Therefore Sebastian et al. assumed that asporin could
directly regulate the initial deposition of hydroxyapatite rather
than acting indirectly by inhibiting TGF-b or BMP-218,22. Given that
TGF-b can interact with asporin (or decorin, biglycan, ﬁbromodulin,
etc.), Sebastian et al. questioned the relevance of asporin as a TGF-b
inhibitor63.
Conclusions and future directions
Our goal was to analyze the literature related to the involvement
of asporin in the development of OA. Evidence, primarily obtained
from investigations using SLRP-deﬁcient mouse models, support-
ing the involvement of SLRPs in the pathogenesis of OA has sur-
faced. The genetically modiﬁed mouse model provides a mean to
understand the molecular mechanisms of OA initiation and pro-
gression. Speciﬁcally, the SLRP-deﬁcient mouse model has advan-
tages over other animal models5. We found various single- and
double-deﬁcient SLRP mouse OA models have been developed5,
however, we found no studies that used an asporin-deﬁcient ani-
mal model. Although asporin is expressed at higher levels in human
cartilage than in mouse articular cartilage, the mouse and human
asporin share 91% amino acid sequence identity in the conﬁrmed
open reading frame (ORF) of 380 amino acid12, suggesting that it
may be possible to simulate an asporin-deﬁcient human model for
OA using the mouse model. It is anticipated that an asporin-
deﬁcient model of OA could be used in future research to better
understand the mechanisms of the disease.
Results from human studies that investigated the association
between the D-repeat polymorphisms and OA susceptibility have
been contradictory. A positive association may exist among pop-
ulations in East Asia. Further investigations should address the
following issues: (1) What are the differences in LRRs (e.g., the
number of different D-repeat alleles) found among East Asians and
West Caucasians? (2) Does a difference among ethnicities depend
upon a difference in the numbers of each D-repeat (e.g., D13 and
D14) or in protective or detrimental characteristics of each D-
repeat? (3) Is there any unknown gene(s) or amino acid sequence
frame that differs with ethnicity that affects the expression of
different D-repeat alleles? (4) Why is asporin involved in OA
development in a site (hand, hip, and knee)-speciﬁc manner?
OA is a major cause of disability in the aging population and is
increasing in its prevalence and social consequences. The present
therapies primarily target effects to alleviate symptoms and
decelerate OA progression, but treatment to prevent or reverse OA
progression is lacking. Approaches aimed at multiple steps of the
pathogenesis of OA are needed to break the chronic cycle of joint
destruction. As stated in our previous review5, the functional link
between ECM proteins, TGF-b activity, and OA suggests that agentscontrolling and modifying the TGF-b-ECM system are promising
targets for the development of new therapeutic strategies for OA.
In addition, some SLRP fragments may be used as biomarkers to
evaluate cartilage metabolism or OA progression74,75. Further in-
vestigations focusing on asporin are needed before treatments can
be developed to diagnose, treat, or slow the degenerative process
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